Cancer as a Therapeutic Agent?

Paper Menu >>

Journal Menu >>

Journal of Cancer Therapy, 2013, 4, 1362-1365

http://dx.doi.org/10.4236/jct.2013.48161 Published Online October 2013 (http://www.scirp.org/journal/jct)

Cancer as a Therapeutic Agent?*

Mario Gosalvez

Laboratorío y Servicío de Bioquímica Experimental (1970-2010), Clínica and Hospital Universitario Puerta de Hierro Madrid and

Majadahonda, Comunidad de Madrid, Spain.

Email: [email protected]

Received September 6th, 2013; revised October 4th, 2013; accepted October 12th, 2013

Copyright © 2013 Mario Gosalvez. This is an open access article distributed under the Creative Commons Attribution License,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

The author, concisely and generically, proposes experimental testing on suitable laboratory animals, in state-of-the-art

international centers endo wed with cancer reversal experimental techniques. Using mild carcinogens to induce more or

less benign growths can be reversed back to a normal state by single or dual strategy: in spinal paralysis by medullar

contusion in young rabbits; for blindness caused by the severing of the optic nerve in sheep; for neural deafness caused

by severing the acoustic nerve in rabbits. If these techniques could be shown to be feasible and successful for higher

order primates and if having then already cured for life a sufficient number of malignant cancers by cancer reversal by

dual strategy in human beings, of course these methods could be then considered for patients.

Keywords: Mild Carcinogenesis and Cancer Reversal; Animal Recoveries from Spinal Paralysis; Blindness and

Deafness; Mitochondrial Filamentation

1. Introduction

I should like to draw your atten tion to some initial possi-

bilities on the use of cancer as a therap eutic agent. Some

years ago, there is going a process which might lead to

the understanding of a defect in mitochondrial filamenta-

tion in the tumoral cell as a basis for a better comprehen-

sion of its nature, cause, diagnosis and treatment [1-10].

My first contribution to these discoveries has simply

been assisted with some pilot experiments and first clini-

cal studies in animal and human malignant tumors [11-

21]. It is only now that the field of mitochondrial fila-

mentation might begin to go forward, hand in hand, at

least, with the most proficient experimental and clinical

cancer research [4-6,9].

This field of mitochondrial filamentation augurs well

for a good harvest in several applications: from the ex-

tension of metabolic life in cases of transitory physio-

logical death [6,22] to an increase of sporting prowess

[3], including degenerative illnesses and aging [6,7,10]

schizophrenia or obesity [6,7], for example. I have re-

cently published my proposal to explain the in timate me-

chanism of the aerobic glycolisis of tumoral cells [8],

based in our studies on th is last in cognita of the n ature of

cancer [1,3,16].

I only have but a few years left in an advisory capacity

on mitochondrial filamentation, and its future applica-

tions before being overtaken by the new generation of

experts. The ball therefore is now in the court of the in-

terested youth. I should now like to explain to your read-

ers, concisely and directly, the possibility of applying

cancer to animal experimental treatments for spinal pa-

ralysis, blindness and neural deafness. There are three

species of creature on which, in my judgment, trials

could be started now by experts: the young rabbit for

spinal paralysis; the young sheep for blindness and the

adult rabbit for deafness. Matters would be ready, possi-

bly, to begin immediately on animals in some centers of

clinical and surgical excellence in the USA, Europe and

Japan.

2. Spinal Paralysis

Up until now, this problem—the interruption of the spi-

nal cord—has been attempted on rats using neural graft-

ing and stem cells, more or less first-order ones. Among

the issues encountered are the impermanence of the solu-

tion and the cancerification of the implant. We firmly

believe that the exquisite embr yonic cell concatenatio n in

time and space for the differentiation continues in the

adult organism on account of the suitable molecular cor-

relations for dedifferentiati on and re di f ferentiat i on.

In such a way, in our opinion, that besides those useful

*An experimental proposal for low order laboratory mammals.

Copyright © 2013 SciRes. JCT

Cancer as a Therapeutic Agent ? 1363

bone marrow transplants in human leukemia, there will

probably be only two ways to replace damaged cells in

the spinal cord of superior mammals:

1) Cancerify cells locally to cells of low malignancy

and subsequently apply reversal techniques back to nor-

mality when the problem has been resolved.

2) Locally inducing the dedifferentiation to stem cells

so as to redifferentiate them subsequently to normal cells.

In respect of the second way, I believe that decades of

study are needed. The first one, I consider, is feasible

now in some very capable centers.

Spinal paralysis should be induced in the recently

weaned bunny rabbit by spinal cord contusion. As soon

as it has been filmed, and its number of movements per

hour determined, following the consolidation of the le-

sion, the pre-carcinogen cocktail-to be metabo lized to the

final medullar carcinogen suitable for the rabbit, should

be injected in few microliters in the neurons immed iately

in front of and behind the spinal cord hiatus.

Naturally, at the moment there are several possibilities

for those local initiators of benign spinal tumor. Only by

trial and error on dozens of rabbits will the best ones

manifest themselves. The cocktails that may work best in

filamented mitochondria and in primary neural cultures,

in addition to adult rabbits, will allow us to experiment

on the miniature pig with chances of a good success rate.

It is considered important, in my opinion, to repeat these

experiments on as many different species as possible.

As soon as a success rate of more than 70 percent is

guaranteed for the generation of a spinal cord tumor,

especially in pigs, reversal back to the normality of a

benign tumor could be started, as soon as the slightest

reactive movement has been observed in the tails of the

stimulated animals.

At that point, very possibly, the comparison of move-

ments per hour would show a marked increase and the

detection by PET-SCAN of the spinal cord tumor would

have yielded some indication of its malignancy. There-

fore, very shortly afterwards, the beginning of the tumor

reversal with techniques solely directed at benign tumor

cells, or by dual strategy, (including therefore cytotoxics

for tumor reducts) could be shown [13-16,20,21].

Following the complete recovery of movement, with-

out any other added toxicity, an observation period of at

least eight weeks will be set up, to ensure that there is no

tumor reappearance and then to progress to the ape and

monkey.

When sufficient monkeys may have been cured com-

pletely the therapy could be considered in volunteers.

Especially in those young tetraplegics previously well-

prepared in suitable centers if these persons could blink

their approval. Having tak en the due assessorial informa-

tion, family advice and insurances, of course, these pro-

cedures could be followed, only if a sufficient number of

human malignant cancers had then cured for life duration

[4-6,9].

3. Neural Blindness

A young sheep would be the animal of choice. All the

optic nerves would have to be cut very cleanly at the best

height of their length, leaving it without sight in one eye.

Neural atrophy would be expected, taking due ophthal-

mologic measures at regular intervals for both eyes, the

sightless and the healthy one.

From that moment, the retinal hyperplasic cocktail

suitable for sheep, a specialization directed at the cells

with aerobic glycolysis, would begin to be administered.

The observation of pre-carcinogenic hyperplasia in the

cells of the retina of both eyes would need to be done

daily at the back of both eyes. The intestinal crypts

would also have to be checked.

In the healthy eye the reversal treatment would be per-

formed locally. For the sightless eye only a local reversal

treatment would be done for the benign cancerification.

When the photon charge tests were almost identical for

both eyes using intracerebral electrophysiological Regis-

ter, the process would be stopped until co mplete cure had

been instated and registered by complete vision returning

to the eye that was sightless, with the healthy eye cov-

ered.

Naturally, the adaptation of the hyperplasic cocktails

and the local benign cancer which function best on sheep,

in order to progress to the ape and monkey and then on to

the human being, would need to be proven with primary

cultures and filamented mitochondria of retinas of the

species in question.

4. Neural Deafness

The cochlea contains neurons that charge metals very

well.

The cocktails of benign cancerification of this organ

must be manufactured as metal complexes suitable to be

digested intracellularly in their target cells. In such a way

as to be able to distinguish similarities between the ear

whose nerve has been cut and the healthy one by in-

tracerebral sound charge resister. Reversal, whether by

single or dual technique, should begin as soon as the deaf

ear can hear. The treatment of the healthy ear must be

local and start from the beginning. At the final stage of

recovery the procedure would be the same as for neural

blindness.

5. Important Considerations

The accumulated research on agents acting on cell hy-

perplasia is very extensive. The collection of agents, hy-

poplasic, hyperplasic, pre-carcinogens and soft carcino-

Copyright © 2013 SciRes. JCT

Cancer as a Therapeutic Agent ?

1364

gens, is very large. The primary culture techniques, of

cells, tissue and organs, is well embedded. Trials on fila-

mented mitochondria [6-10,21] are easy to perform and

will represent a very rapid screen ing of hundred s of co m-

pounds per month capable of returning more or less neo-

plastic cells to their state of normality.

It is recommended that the proposed studies be per-

formed, in a calm and serene manner, with the collabora-

tion of all, especially doctors and chemists of different

specializations, to achieve this possible step forwards. If

at some future point these studies were successful on

apes, the techniques could be considered for patients. Of

course, only when the complete cure of cancer diseases

had been obtained in humans [4-6,9].

6. Discussion

A new adventure of ideas that surpasses the avenues of

habitual thinking may be taken as too daring by those

experts who have the right equilibrium between the past

and the path to the fu ture. Our prop ositio n, first of all, fo r

animal experimentation, comes after having observed not

too much progress with the stem cell approach in the last

decade, with science still not counting on localized tech-

niques of adequate stem cell formation to resolve clearly

these problems.

We have recently published on-line a concise account

of our methodological expertise in the isolation and assay

of filamented mitochondria and some proposals for pos-

sible future applications of this now emerging field [1,2,

4-10,21,22]. A search for private national and interna-

tional financing for this and other future possible appli-

cations in this area of molecular physiology and medi-

cine has already been started.

7. Conclusions

The due opportunity for this proposal in laboratory ani-

mals is timidly requested to the scientific community. It

would be almost ready for the task with the security that

if it should result in another failure, at least we would

have clarified possible new ways. This proposal brings

out a humble request for a combination of neurologists

and oncologists of various types working closely together

for some years on several animal species.

I considered that this, perhaps too daring an idea,

could be contemplated with attention by the Journal of

Cancer Therapy. Other journals declined previously rap-

idly and kindly to publish this paper. Most surely based

on the lack of expertise on one or another of the two as-

pects considered in the proposal: Cancer and Neurolog y.

8. Acknowledgements

The author is grateful to Mr. Andrew Guy for his review

of the English text and for his inestimable help in the

initial submission process.

REFERENCES

[1] M. Gosalvez, “Oxygen Production by Filament Mito-

chondria. Importance in Cancer and Neurodegeneration,”

Anales de la Real Academia Nacional de Medicina (Ma-

drid) Spain, Vol. 115, No. 3, 1998, pp. 747-756.

[2] M. Gosalvez, “Reversion of Cancer and Mitochondrial

Filamentation,” Anales de la Real Academia Nacional de

Medicina (Madrid) Spain, Vol. 117, No. 4, 2000, pp. 825-

834.

[3] M. Gosalvez and S. Weinhouse, “Control Mechanism of

Oxygen and Glucose Utilization in Tumors,” Advances in

Experimental Biology and Medicine, Vol. 75, 1976, pp.

587-596.

http://dx.doi.org/10.1007/978-1-4684-3273-2_69

[4] M. Gosalvez, “Mitochondrial Filamentation,” 101th AACR

Meeting, Washington DC, 17-21 April 2010, pp. 3-7.

[5] M. Gosalvez, “Reversal of Cancer by Dual Strategy: A

New Molecular Target,” 103rd AACR Meeting, Chicago,

31 March-4 April 2012, p. 1118.

[6] M. Gosalvez, “Mitochondrial Filamentation: Some Meth-

ods of Isolation and Assay,” IOSR Journal of Pharmacy

and Biological Sciences, Vol. 4, No. 4, 2012, pp. 37-39.

http://dx.doi.org/10.9790/3008-0443739

[7] M. Gosalvez, “Methods to Be Developed for Some First

Applications of Mitochondrial Filamentation,” Open Jour-

nal of Biophysics, Vol. 3, No. 1A, 2013, pp. 51-53.

http://dx.doi.org/10.4236/ojbiphy.2013.31A006

[8] M. Gosalvez, “Metabolic Control of Respiration and Gly-

colysis of Tumoral Cells,” Advances in Biological Chem-

istry, Vol. 3, No. 1, 2013, pp. 86-89.

http://dx.doi.org/10.4236/abc.2013.31011

[9] M. Gosalvez, “Reversal of Cancer by Dual Strategy?” Jour-

nal of Cancer Therapy, Vol. 3, No. 4, 2013, pp. 518-520.

[10] M. Gosalvez, “Mitochondrial Filamentation: A Therapeu-

tic Target for Neurodegeneration and Aging?” Journal of

Alzheimer’s Di seas e & and Other Dementias, Vol. 28, No.

5, 2013, pp. 423-426.

http://dx.doi.org/10.1177/1533317513494451

[11] L. Lopez-Alarcon, et al., “Quantitative Determination of

the Degree of Differentiation of Mammary Tumors by

Pyruvate Kinase Analysis,” Cancer Research, Vol. 41,

No. 5, 1981, pp. 2019-2020.

[12] A. Brugarolas and M. Gosalvez, “Preliminary Clinical

Results with Norgamen (thioproline) and Revercan (2-

Amino-thiazoline): The First Inducers of Reverse Trans-

formation,” Adjuvant Therapies of Cancer, Recent Results

in Cancer Research, Vol. 80, 1982, pp. 346-350.

http://dx.doi.org/10.1007/978-3-642-81685-7_56

[13] H. Cortes- Funes, et al., “Que lamycin: A Summary of Phase

I Clinical Trials,” Recent Results in Cancer Research, Vol.

74, No. , 1980, pp. 2000-2009.

http://dx.doi.org/10.1007/978-3-642-81488-4_25

[14] M. Gosalvez and A. Brugarolas, “Treatment of Cancer by

an Inducer of Reverse Transformation,” The Lancet, Vol.

1, No. 8159, 1980, pp. 68-70.

Copyright © 2013 SciRes. JCT

Cancer as a Therapeutic Agent ?

Copyright © 2013 SciRes. JCT

1365

[15] M. Gosalvez y Gosalvez, “Basis for Design of Pharma-

cological Effectors Acting on Plasma Membrane Recep-

tors,” Biochemical Society Transactions, Vol. 1, 1981, pp.

151-152.

[16] M. Gosalvez, “The Zipper Mechanism,” Comercial Mal-

var, Madrid, 1982.

[17] M. Gosalvez, “Carcinogenesis with the Insecticide Rote-

none,” Life Sciences, Vol. 32, No. 8, 1983, pp. 809-816.

http://dx.doi.org/10.1016/0024-3205(83)90216-3

[18] M. Gosalvez, “Thioproline and the Reversal of Cancer,”

The Lancet, Vol. 1, No. 8333, 1983, p. 1118.

[19] M. Gosalvez, et al., “Spectral and Metabolic Characteris-

tics of Mitochondrial Fractions Isolated from Rotenone

Induced Tumours,” British Journal of Cancer, Vol. 36,

No. 2, 1977, pp. 243-252.

http://dx.doi.org/10.1038/bjc.1977.184

[20] M. Gosalvez, et al., “Treatment of Intravenous Leukemia

1210 Transplants with Tumor Modifiers. Redoubt Cyto-

toxics and Minor Tranquilizers,” Aminoacids Chemistry,

Biology and Medicine, Escom Sciences Publishers, Lei-

den, 1990, pp. 704-711.

[21] M. Gosalvez, “Cancer Reversal by Dual Strategy,” Edito-

rial Gober, Madrid, 1992.

[22] M. Gosalvez, “Extension of Metabolic Life. Abstract,”

Proceedings of the 36th ISOTT Meeting, Sapporo, 3-7

August 2008, p. 52.